Kornimate/medical-research-clean huggingface dataset:
ai colorectal polyp detection

Conditions: Polyp Colorectal; Adenoma Colon

Summary: this study is intended to demonstrate the superiority of colorectal polyp detection using computer-assisted colonoscopy compared to conventional colonoscopy.


Eligibility criteria:
inclusion criteria: * average risk subjects undergoing their first colonoscopy (screening) or follow-up colonoscopy for previous history of polyps (surveillance interval of 3 years or greater) * patients aged 45 or older * patients who can provide an informed consent exclusion criteria: * patients with history of colon resection, inflammatory bowel disease (ibd), familial adenomatous polyposis (fap), severe comorbidity, including end-stage cardiovascular/pulmonary/liver/renal disease * patients who are pregnant or are planning pregnancy during study period * patients who are not able to or refuse to give informed consent
protective immune mechanisms in alcoholic hepatitis

Conditions: Alcoholic Hepatitis

Summary: the purpose of this study is to investigate the production, effects and interactions of the hepato-protective cytokine interleukine (il)-22 in patients with alcoholic hepatitis.

the investigators will study hepatic biopsies from patients with alcoholic hepatitis. in these biopsies, the investigators will assess the production of il-22 and which cells produce the cytokine. the investigators will study the expression of the il-22 receptor and also the production of the il-22 binding protein, which can inhibit the actions of the cytokine.

Eligibility criteria:
inclusion criteria: * diagnosis of alcoholic hepatitis: * relevant history of alcohol consumption (\>40g/day for a minimum of 6 months with cessation of consumption no earlier than 3 months prior to admission) * bilirubin \> 80 mol/l * neutrophil granulocytes \> 10x10\^9/l * exclusion of other liver pathology including biliary disease * histological verification on liver biopsy * written, informed consent exclusion criteria: * other chronic inflammatory or autoimmune diseases * severe, acute bacterial infection (peritonitis, sepsis, pneumonia, urinary tract infection etc.) * cancer * prednisolon or pentoxifylline treatment within the past 8 weeks * pregnancy

Keywords: alcoholic hepatitis il-22 kupffer cells
a clinical trial about the safety of surgical treatment in severe primary pontine hemorrhage

Conditions: Cerebrovascular Disorders; Pontine Hemorrhage; Primary; Surgery

Summary: primary pontine hemorrhage (pph) is not common but is the most catastrophic subtype of intracerebral hemorrhage, with acute mortality between 30% and 60%. for severe pph, defined as glasgow coma score (gcs) \<8 and hematoma volume≥5ml, the mortality rate is as high as 80-100%. guidelines from the american heart association and european stroke organization do not make definite specifications. more than a century after finkelnburg first explored the brainstem for hematoma, however, plenty of researches have shown surgery can save lives and improve the prognosis for selective patients and can be an effective and safe treatment. this study is proposed to validate the safety of surgical treatment in severe primary pontine hemorrhage.

the study is being conducted from jan 2022 to nov 2024 in 20 neurosurgical units. this stipe trial is an investigator-initiated, parallel (3:1 to surgical he or mt), multi-centre, randomized controlled open-label trial following the consolidated standards of reporting trials (consort) guidelines and will be conducted from jan 2022 to nov 2024 in 20 tertiary hospitals in china. the flow chart of the clinical trial is presented in figure 1. neurosurgeons involved in the study are senior investigators with good clinical experience in spph management. moreover, all investigators are well trained centrally according to the requirements.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of pph: patients have acute hemorrhage mainly in pons with a definite history of hypertension. 2. gcs 5\~7 and hv≥5ml on admission (the hv in intraventricular system being excluded). 3. family members consenting to randomize and signing informed consent form (icf). 4. time from onset to admission less than 24 hours. 5. age:18 years or older. exclusion criteria: 1. structural lesions such as brainstem cavernous malformation, arteriovenous malformation, aneurysm, tumor apoplexy. 2. gcs≥8 and hv\<5ml. 3. time from onset to admission over 24 hours. 4. patients with platelet count \ 1.4, or an elevated prothrombin time (pt) and activated partial thromboplastin time (aptt). 5. multiple ich. 6. accompanying hydrocephalus that requires surgical management 7. irreversible brainstem failure (bilateral fixed, dilated pupils and extensor motor posturing, gcs≤4). 8. a previous history of ich. 9. any serious concurrent illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease. 10. pregnant patients. 11. patients' family members refuse he. 12. any other condition that the investigator believes would present a significant hazard to the subject if the investigational therapy were initiated. 13. participating in another simultaneous trial of ich treatment.
factors affecting treatment expectations in chronic neck pain

Conditions: Neck Pain Chronic

Summary: the aim of this study was to determine which factors affect treatment expectations in individuals with chronic neck pain.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18-80 years of both sexes diagnosed with chronic neck pain by a physical medicine and rehabilitation specialist will be included in the study. volunteers who sign the consent form following verbal information will be included in the study. exclusion criteria: * the presence of instability in the neck joints, trauma within the last year, severe osteoporosis, previous neck surgery, physical therapy within the last 6 months, neurological findings or radiculopathy.
trans-nasal complete nasolabial cyst excision

Conditions: Nasolabial Cyst

Summary: background: nasolabial cysts are rare benign epithelial nonodontogenic soft tissue cysts arising in the nasal alar region. sublabial excision or transnasal endoscopic marsupialization is the standard treatment. patients and methods: between 2019 and 2022, a descriptive retrospective study, including 20 patients who presented with nasolabial cysts, was conducted.

a retrospective study of patients who were presented in the period from 2019 to 2022, with nasolabial cysts. patients' files were checked for demographic data, clinical presentation, preoperative radiological investigations, histopathology, surgical approach, complications, and outcome. technique: the surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). an incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. the mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. during dissection, cyst content is usually drained. the whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. if mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.

Eligibility criteria:
inclusion criteria: •nasolabial cyst exclusion criteria: * recurrent cases * previous operated

Keywords: nasoalveolar - nasolabial - klestadt's - cyst
organ-preservative therapy of bladder cancer with radiotherapy or radiochemotherapy combined with hyperthermia

Conditions: Bladder Cancer

Summary: analysis of the efficacy and the compatibility of deep regional hyperthermia in combination with radiotherapy and chemoradiotherapy in bladder cancer


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histologically confirmed bladder cancer * m0 * ecog-performance status ≤ 2 * informed consent exclusion criteria: * pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy * cardiac pacemaker * myocardial infarction within the past 12 months * congestive heart failure * complete bundle branch block * new york heart association (nyha) class iii or iv heart disease * disease that would preclude tur, chemoradiation or deep regional hyperthermia * metal implants (lenght \> 2cm or dense clusters of marker clips in the pelvis) * active or therapy-resistent bladder infections * pre-existing or concommitant immunodeficiency syndrom * pregnant or lactating women * patients not willing to use effective contraception during and up to 6 months after therapy

Keywords: bladder cancer hyperthermia radiotherapy chemotherapy
evaluation of the effectiveness of home-use desensitizing agents on dentin hypersensitivity

Conditions: Dentin Sensitivity

Summary: dentin sensitivity is one of the most common problems in society and affects the quality of life related to oral health. agents such as toothpaste, mouthwash, and dental cream are home-type desensitizing agents used as the first step in the treatment of dentin hypersensitivity. a total of 180 individuals with dentin sensitivity will be included in the study and the individuals will be randomly divided into 6 groups. individuals in the 1st group will be given arginine-containing toothpaste, individuals in the 2nd group will be given novamin-containing toothpaste, individuals in the 3rd group will be given propolis-containing toothpaste, individuals in the 4th group will be given casein phosphopeptide amorphous calcium phosphate-containing dental cream, and individuals in the 5th group will be given mouthwash containing potassium nitrate. classic toothpaste with 1450 ppm fluoride will be distributed to individuals in the control group, which is the 6th group. the dentin hypersensitivity experience questionnaire (dheq-15), consisting of 15 questions, will be used to evaluate dentin sensitivity. visual analogue scale (vas) will be used to determine the individual's pain score in dentin sensitivity, and the individual will be asked to score the intensity of pain experienced between 0-10 points. finally, in the evaluation of dentin sensitivity, a single dentist will apply air to the cervix of the tooth from a distance of 1 cm for 1 second, and the schiff sensitivity scale score will be determined through clinical examination. a score between 0 and 3 will be determined by the dentist according to the patient's response to the air stimulus. the effectiveness of the home-use desensitizing agents used in the treatment of dentin hypersensitivity was evaluated with dheq-15, vas and schiff sensitivity scale; baseline, 4th and 8th week scores will be compared.


Eligibility criteria:
inclusion criteria: * between 18-70 years old * general health condition is good * individuals with sensitivity in 2 or more non-adjacent teeth exclusion criteria: * pregnant or breastfeeding women * advanced periodontal diseases * chronic diseases that may affect the study results * major oral pathologies * use of anticonvulsant, antihistamine, antidepressant, sedative, tranquilizer medication * use of desensitizing paste in the last 3 months * individuals who have been treated for periodontal disease in the last 12 months

Keywords: arginine novamin propolis
can vitamin d3 supplementation affect treatment outcomes in patients with depression

Conditions: Depression

Summary: the purpose of this study is to investigate whether patients with depression should be offered vitamin d supplements, or it has no significance in relation to treatment outcomes.

vitamin d3 is produced in the skin after exposure to ultraviolet b light from the sun. vitamin d3 is metabolised sequential in the liver into 25-hydroxy-vitamin d \[25(oh)d\], which is the storage form of vitamin d in the body, and then in the kidney into the steroid hormone, 1a,25-dihydroxyvitamin 1a,25-dihydroxyvitamin d \[1,25(oh)2d\]. at higher latitudes ultraviolet b light is stopped by the atmosphere during winter season. half of danes have low levels of \[25(oh)d\] in the blood and especially in the early spring months the levels of \[25(oh)d\] are low. in addition, vitamin d3 is absorbed through the gut from vitamin d-rich food sources. but several studies show that it is not possible through a recommended diet, which consists of 300 g of fish per week to consume adequate amounts of vitamin d3. new research suggests link between vitamin d3 and brain function.in the central nervous system (cns) there are specific nuclear receptors for 1,25(oh)2d (vdr) and the enzymes necessary for the hydroxylation of 25(oh)d to 1,25(oh)2d are also present in cns. in clinical studies, low serum levels of 25(oh)d, have been associated with reduced cognitive function, anxiety and depression. the objective of this randomized clinical trial is to investigate whether patients with depression should be offered vitamin d3 supplements, or it has no significance in relation to treatment outcomes. the study is carried out in mental health services in the region of southern denmark for 24 weeks and offered to patients being treated for depression (treatment as usual) plus 70μg vitamin d3 or placebo.

Eligibility criteria:
inclusion criteria * clinical diagnosis unipolar depression exclusion criteria: * clinical diagnosis sarcoidoses * tuberculosis * bipolar affective disorder * schizophrenia * hypercalcemia * hyperphosphatemia * electroconvulsive treatment for the last 6 months * primary diagnosis addiction

Keywords: serum 25-hydroxyvitamin d,vitamin d supplement, depression, parathyroid hormone
comparison of the effects of ordinary and differential learning based physiotherapy on subjects with ischemic stroke torso control, balance and gait in the second phase of rehabilitation

Conditions: Ischemic Stroke

Summary: the purpose of this study was to assess the effect or ordinary and differential learning based physiotherapy for torso control, balance and gait on subjects with ischemic stroke in the second phase of rehabilitation

ischemic stroke is still the second most common cause of death and one of the leading causes of disability worldwide. half of all individuals with ischemic stroke do not regain lost body functions until the end of life. individuals with ischemic stroke are most likely to have impaired cognitive, sensory, and motor functions, but the greatest challenge for health care professionals is impaired motor skills caused by motor nerve cell damage. in order to minimize the degree of disability, it is important to respond quickly to a person's condition. because it has been shown that lost functions can be taken over by adjacent, non-stroke-affected areas of the cerebral cortex, early rehabilitation is a key factor that can help prevent function limitation by acting in conjunction with spontaneous recovery of body function. the aim of the study is to assess the effect or ordinary and differential learning based physiotherapy for torso control, balance and gait on subjects with ischemic stroke in the second phase of rehabilitation. the study was approved by committee on biomedical research ethics of kaunas region (2020-06-30 no.bec-kn(b)-263).

Eligibility criteria:
inclusion criteria: * patients rehabilitated in neurorabilitation departmen of lithuanian university of health sciences hospital kauno kliniko in the second stage of rehabilitation; * stroke for the first time; * 45-74 m. age; * able to go with aids; * voluntary consent to participate in the study.
mnk-6105 for patients with cirrhosis and high ammonia levels affecting brain function

Conditions: Hepatic Encephalopathy

Summary: this study is for patients with cirrhosis and hepatic encephalopathy who are in the hospital. this means they have a high ammonia level which is affecting their brain function. all patients will receive the standard of (regular) care. each will have an equal chance (like flipping a coin) of receiving the experimental drug or placebo along with the standard care. each patient will have tests during the first 24 hours, receive treatment for up to 5 days, and have 30 days of follow-up.


Eligibility criteria:
inclusion criteria: to be included, a patient must: * be the age of majority in their country (considered an adult) * be male or non-pregnant, non-lactating female * have ohe (stage 2, 3, or 4) as a complication of cirrhosis * have been hospitalized within 24 hours before start of infusion (soi) * receive at least 6 hours of soc treatment exclusion criteria: patients will be excluded if they have inadequate renal function or any other disease, laboratory value, or condition (including allergy, drug use or treatments) that per protocol or in the opinion of the investigator, might increase the risk of compromising: 1. health or well-being of the patient 2. safety of study staff 3. analysis of results

Keywords: overt he diagnosis
healthy volunteer pilot study using 3 types of modified release formulations of firategrast to investigate how quickly absorption from the digestive system takes place.

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: this study will investigate how 3 new types of drug formulations are absorbed by the body. this study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving. the study involves all volunteers receiving all 3 different formulations, as a single dose, and there is no placebo (dummy-drug; no active ingredient) in this study. volunteers will also receive a single dose of a formulation used in previous trials (reference formulation), so as a proper comparison with the new formulations can be made. one of the new formulations will also be administered along with food, to assess if the drug performs or is absorbed differently.

the present study will investigate the tolerability and pharmacokinetics of single oral doses of firategrast administered as the existing immediate release tablet formulation and as three modified release tablet formulations designed to release drug over differing relase rates. the range of release rates is expected to give preliminary information on the performance of a matrix modified release formulation for use in future efficacy studies. subjects will receive each formulation in the fasted state in a randomised 4-part single dose crossover fashion. based on the review of pharmacokinetic data from at least the first two study sessions, subjects may also receive a fifth dose of firategrast, administered after a high fat meal. the formulation administered with food will be chosen based upon pharmacokinetic data from previous dose sessions. doses administered will be different with respect to gender; the doses are expected to result in similar exposures across the genders.

Eligibility criteria:
inclusion criteria: * male or female, aged 18 to 65 yrs inclusive * healthy, as determined by study physician * capable of giving informed consent exclusion criteria: * positive drugs of abuse result * positive for hiv or hepatitis b and/or c viruses * history of alcohol consumption in excess of average recommended weekly intake (more than 21 units for males, more than 14 units for females) * participation in a clinical trial within 90 days of scheduled first dose

Keywords: healthy volunteers firategrast pharmacokinetics modified release
pci imaging system in pediatric ophthalmology

Conditions: Retinoblastoma

Summary: the purpose of this study is to compare the retcam (clarity medical systems, pleasanton, ca) to a new prototype pediatric imaging system, cosmos, produced by phoenix clinical incorporated (pci) (pleasanton, ca).


Eligibility criteria:
* exclusion criteria: * any patient who has a cloudy cornea. * any patient whose retcam imaging exam easily produces blanching of the optic nerve in the normal course of imaging. * any patient who has consented to the procedure, but whose course of examination has filled the time allotted, leaving no time to evaluate the cosmos. * inclusion criteria: * current patients undergoing clinically indicated eua and retcam imaging for surveillance and treatment of ophthalmic conditions at the hospital for sick children.

Keywords: diagnostic imaging retina pediatrics
real-world data of nivolumab in pre-treated nsclc

Conditions: Non Small Cell Lung Cancer

Summary: nivolumab is an approved treatment option for patients with previously treated advanced nsclc, based on the survival benefit shown versus docetaxel in randomized phase iii trials in second line. however, the profile of treatment and even patient outcomes are often different in routine clinical practice than in a clinical trial setting. furthermore, the financial impact of an approved therapy is often largely unknown. this study will record the efficacy and tolerability of nivolumab in previously treated patients with nsclc and describe the treatment patterns and economic impact in real-world settings in greece.

patients with advanced nsclc who had received nivolumab as 2nd line and beyond, between october 2015 and november 2019, in hecog clinical centres in greece, were enrolled. information regarding detailed patient and treatment characteristics including post-nivolumab therapies, efficacy, and safety data of nivolumab treatment and additionally data on costs and other economic values are collected, analysed and compared with historical data in order to describe the real-world patterns of nivolumab use in 2nd line nsclc therapy in greece.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of advanced squamous or non-squamous nsclc (histologically or cytologically confirmed), who had relapsed after 1 prior platinum-based systemic treatment and who received treatment with nivolumab * nivolumab treatment received in participating hecog centres between october 2015 and november 2019 * alive patients must have signed and dated the study approved written informed consent form in accordance with regulatory and institutional guidelines, obtained before any protocol-related procedures that are not part of normal patient care. exclusion criteria: * alive patients who do not want to sign and date the study approved written informed consent form * patients that participated in any other clinical trial prior or after nivolumab treatment
study of single and double bundle anterior cruciate ligament (acl) graft cross-sectional dimensions

Conditions: Rupture of Anterior Cruciate Ligament

Summary: to study the difference between single and double bundle acl graft cross-sectional dimensions compared with native acl using postoperative 3-d mri.

the investigators divide 100 patients with acl rupture into 2 groups. group a undergo single bundle anterior cruciate ligament reconstruction (aclr). group b undergo double bundle acl reconstruction. at 3-6 weeks post operation, all the patients undergo 3-d mri examination of both knees. the investigators reconstruct 3-d models of reconstructed acl and native acl, and compare the difference between single and double bundle graft.

Eligibility criteria:
inclusion criteria: * acl rupture patients aged between 10 to 50 years exclusion criteria: * combined severe injuries to the operated knee (additional ligament rupture, major meniscus loss, patella instability, cartilage damage \>2°, pathologic leg axis deviation) * any injury or surgery to the contralateral knee * any inflammatory or systemic disease, neuromuscular disease in the lower limbs,any recent knee infection

Keywords: anterior cruciate ligament reconstruction